康方生物(09926.HK)明星双抗药物依沃西单抗新增适应证获批的利好消息,不仅没有对公司股价构成利好,反而进一步在“带崩”股价。4月28日,康方生物股价以大跌11.83%报收,问题出现在依沃西单抗的总生存期(OS)数据上,市场认为,在该数据上,依沃西单抗相较“全球药王”K药有临床获益,但未获得统计学显著性。事情的真相到底如何?OS数据不及预期?近日,中国药监局批准了依沃西单抗第二个适应证上市,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.